MedElevator
Войти в исследования Vaccine · 2026
Chikungunya virus virus-like particle vaccine (VIMKUNYA) elicits cross-neutralization across CHIKV lineages and against other alphaviruses after just one dose.
СтатьяКлиническое исследование II фазыНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gardner Christina L, Brown Nikia N, Brown Jennifer L, Morello Christopher S, Sandesara Rohini G, Tindale Lauren C, Stoddard Steven T, Warfield Kelly L, Vang Lo, Burke Crystal W
Аннотация
BACKGROUND: Chikungunya virus (CHIKV) is a mosquito-borne virus that has spread widely and infected millions of people. CHIKV can cause both acute and chronic polyarthralgia that can be debilitating. The CHIKV virus-like particle (VLP) vaccine, VIMKUNYA™, is approved for use in the US, EU/EEA, UK, and Switzerland.
METHODS: The aim of this study was two-fold: 1) determine if a single dose of CHIKV VLP vaccine generates cross-neutralizing antibodies against diverse CHIKV strains representing major viral lineages, as well as other arthritogenic alphaviruses, and 2) determine if previous alphavirus vaccination alters the ability to generate cross-neutralizing antibodies after CHIKV VLP vaccination. In this analysis, sera from participants enrolled in a phase 2 study were assessed for neutralizing activity against multiple CHIKV strains and related alphaviruses.
RESULTS: A single vaccination with CHIKV VLP vaccine induced cross-neutralizing antibodies against multiple lineages of CHIKV and generated measurable cross-neutralizing activity against several related arthritogenic alphaviruses. Importantly, individuals with prior history of alphavirus vaccination exhibited immune responses comparable to alphavirus-naïve participants, indicating that earlier exposure did not hinder the ability to mount a strong CHIKV-specific or cross-reactive antibody response.
CONCLUSIONS: These results highlight the broad immunogenic potential of CHIKV VLP vaccine and support its suitability across diverse populations, including individuals with prior alphavirus exposure, as previous vaccination did not diminish the ability to generate robust CHIKV-specific or cross-neutralizing antibody responses against CHIKV and other arthritogenic alphaviruses.
METHODS: The aim of this study was two-fold: 1) determine if a single dose of CHIKV VLP vaccine generates cross-neutralizing antibodies against diverse CHIKV strains representing major viral lineages, as well as other arthritogenic alphaviruses, and 2) determine if previous alphavirus vaccination alters the ability to generate cross-neutralizing antibodies after CHIKV VLP vaccination. In this analysis, sera from participants enrolled in a phase 2 study were assessed for neutralizing activity against multiple CHIKV strains and related alphaviruses.
RESULTS: A single vaccination with CHIKV VLP vaccine induced cross-neutralizing antibodies against multiple lineages of CHIKV and generated measurable cross-neutralizing activity against several related arthritogenic alphaviruses. Importantly, individuals with prior history of alphavirus vaccination exhibited immune responses comparable to alphavirus-naïve participants, indicating that earlier exposure did not hinder the ability to mount a strong CHIKV-specific or cross-reactive antibody response.
CONCLUSIONS: These results highlight the broad immunogenic potential of CHIKV VLP vaccine and support its suitability across diverse populations, including individuals with prior alphavirus exposure, as previous vaccination did not diminish the ability to generate robust CHIKV-specific or cross-neutralizing antibody responses against CHIKV and other arthritogenic alphaviruses.